Marimed (MRMD) Other financing activities (2013 - 2023)

Marimed (MRMD) posted quarterly Other financing activities of $74000.0 for Q3 2023, up 111.43% quarter-over-quarter from $35000.0 in Q2 2023.

Marimed (MRMD) Other financing activities (2013 - 2023) Analysis & Trends

Marimed (MRMD) has reported Other financing activities for 9 consecutive years, with $74000.0 the latest figure, recorded in Q3 2023.

In Q3 2023, Other financing activities changed N/A year-over-year to $74000.0; the TTM figure through Dec 2024 stood at $74000.0 (down 32.11% YoY), while the FY2023 annual figure was $109000.0, up 990.0% from the prior year.
Other financing activities rose to $74000.0 in Q3 2023 per MRMD's latest filing, from $35000.0 in the prior quarter.
Across five years, Other financing activities topped out at $586642.0 in Q2 2019 and bottomed at -$514942.0 in Q4 2019.
Historically, Other financing activities has averaged $22590.9 across 4 years, with a median of $10000.0 in 2019.
On a YoY basis, Other financing activities climbed as much as 7094.53% in 2019 and fell as far as 397.46% in 2019.
Marimed's Other financing activities stood at -$514942.0 in 2019, then jumped by 89.51% to -$54000.0 in 2021, then jumped by 105.56% to $3000.0 in 2022, then soared by 2366.67% to $74000.0 in 2023.
Business Quant data shows MRMD's Other financing activities at $74000.0 in Q3 2023, $35000.0 in Q2 2023, and $3000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Marimed	30.77 Mn	22.33 Mn	16.23 Mn

Download Data